July 01, 2013
1 min read
Save

OSN Retina 150 Survey

Do you already recommend a supplement formulation that includes lutein and zeaxanthin in patients with macular degeneration?

Perspective

Timothy W. Olsen, MD

Timothy W. Olsen

I have recommended the AREDS formulation that includes lutein (10 mg) and zeaxanthin (2 mg) without beta carotene for approximately 6 years. This formulation is also referred to as the “smoker’s version” of the AREDS supplement, with rationale based on a Danish meta-analysis that associated a higher mortality when supplements contained either vitamin A or beta carotene supplementation. In addition, lutein and zeaxanthin are associated with a healthy diet and have antioxidant properties. A direct nutritional association was being measured in the macular pigmentation in primate studies. The AREDS2 data confirm the use of these supplements for AMD patients who have high-risk features.

Timothy W. Olsen, MD
Disclosure: Olsen receives no industry support.

References:
Bjelakovic G, et al. JAMA. 2007;doi:10.1001/jama.297.8.842.
Neuringer M, et al. Invest Ophthalmol Vis Sci. 2004;doi:10.1167/iovs.02-1243.

Do you or would you recommend supplements that contain omega-3 fatty acids in patients with macular degeneration, even though AREDS2 results do not generally support their use in that population?

Perspective

Timothy W. Olsen, MD

Timothy W. Olsen

No, not specifically using a supplement for AMD. My recommendation is based on the results of AREDS2. However, I do still recommend eating fish rich in omega-3 (ie, salmon) and, specifically, not deep-fried preparation of the fish (it destroys the omega-3). One should discuss proper food preparation with patients. Grilled or broiled fish, such as salmon, is an excellent dietary source of omega-3 fatty acid. Importantly, the dietary questionnaire survey from AREDS indicated that the highest quartile for dietary intake of omega-3 had an approximately 30% lower risk of developing advanced forms of AMD at 12 years. There is also evidence in the cardiac literature of the benefits of omega-3 for reducing myocardial death by optimizing cardiac conduction. Therefore, I defer supplementation use to the cardiologist.

Timothy W. Olsen, MD
Disclosure: Olsen receives no industry support.

References:
Burr ML, et al. Lancet. 1989;2(8666):757-761.
Reiffel JA, et al. Am J Cardiol. 2006;doi:10.1016/j.amjcard.2005.12.027.
Sangiovanni JP, et al. Am J Clin Nutr. 2009;doi:10.3945/ajcn.2009.27594.